Análise da segurança e eficácia dos medicamentos antivirais para o tratamento da varíola dos macacos: uma revisão integrativa
Analysis of the safety and efficacy of antiviral drugs for the treatment of monkeypox: an integrative review
DOI:
https://doi.org/10.61223/coopex.v14i1.113Palavras-chave:
Varíola dos Macacos; Antivirais; Tecovirimat; Brincidofovir; Cidofovir.Resumo
Objetivo: Avaliar a segurança, a eficácia e uso de antivirais como tecovirimat, brincidofovir, cidofovir, entre outros, de acordo com as pesquisas recentes em humanos, animais e in vitro. Métodos: Revisão integrativa, executada em seis fases, utilizando-se os Descritores em Ciências da Saúde em inglês monkeypox AND (tecovirimat OR "Antiviral Agents"). Para isso, foram usadas as bases de dados U.S. National Library of Medicine (PUBMED), Biblioteca Virtual em Saúde (BVS) e Scientific Electronic Library Online (SCIELO). Assim, foram identificados 172 artigos, submetidos aos critérios de inclusão: idioma (inglês e português) e ano de publicação (últimos 5 anos) e aos critérios de exclusão, limitando artigos repetidos e que não respondiam ao problema da pesquisa, restando 35 artigos. Resultados: Dentre os antivirais avaliados, o tecovirimat sugere o melhor perfil de segurança nos modelos avaliados, além de um perfil de eficácia maior quando comparado aos demais. Conclusão: Pode-se concluir que o uso de antivirais no tratamento da varíola dos macacos em relação a segurança e a eficácia no combate a doença é majoritariamente favorável. Entretanto, as conclusões ainda não são totalmente precisas, tendo em vista a limitação dos escassos ensaios conduzidos em humanos, sendo necessários estudos em larga escala para melhor elucidar os perfis de segurança e eficácia dos medicamentos antivirais.
Referências
ADLER, H. et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. The Lancet. Infectious Diseases, v. 22, n. 8, p. 1153–1162, ago. 2022.
AJMERA, K. M. et al. Monkeypox - An emerging pandemic. IDCases, v. 29, p. e01587, 2022.
AL-MUSA, A.; CHOU, J.; LABERE, B. The resurgence of a neglected orthopoxvirus: Immunologic and clinical aspects of monkeypox virus infections over the past six decades. Clinical Immunology (Orlando, Fla.), v. 243, p. 109108, out. 2022.
BEER, E. M.; RAO, V. B. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLOS Neglected Tropical Diseases, v. 13, n. 10, p. e0007791, 16 out. 2019.
CARVALHO, T. The unknown efficacy of tecovirimat against monkeypox. Nature Medicine, v. 28, n. 11, p. 2224–2225, nov. 2022.
CHAKRABORTY, S. et al. Clinical management, antiviral drugs and immunotherapeutics for treating monkeypox. An update on current knowledge and futuristic prospects. International Journal of Surgery (London, England), v. 105, p. 106847, set. 2022.
CHEEMA, Asfand Yar et al. Monkeypox: a review of clinical features, diagnosis, and treatment. Cureus, [S.L.], v. 14, n. 7, p. 1-4, 11 jul. 2022. Cureus, Inc.. http://dx.doi.org/10.7759/cureus.26756.
CHOWDHURY, S. R.; DATTA, P. K.; MAITRA, S. Monkeypox and its pandemic potential: what the anaesthetist should know. British Journal of Anaesthesia, v. 129, n. 3, p. e49–e52, set. 2022.
CRONIN, M. A.; GEORGE, E. The Why and How of the Integrative Review. Organizational Research Methods, p. 109442812093550, 2020. Disponível em: https://doi.org/10.1177/1094428120935507. Acesso em: 10 nov. 2022
DAMON, Inger K. et al. Status of human monkeypox: clinical disease, epidemiology and research. Vaccine, v. 29, p. 54-59, dez. 2011.
DASHRAATH, P. et al. Monkeypox in pregnancy: virology, clinical presentation, and obstetric management. American Journal of Obstetrics and Gynecology, p. S0002- 9378(22)00651–2, 17 ago. 2022.
DESAI, A. N. et al. Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection. JAMA, v. 328, n. 13, p. 1348, 4 out. 2022.
DESHMUKH, P. et al. Monkeypox: What do we know so far? A short narrative review of literature. The Journal of the Association of Physicians of India, v. 70, n. 7, p. 11–12, jul. 2022.
FOOD AND DRUG ADMINISTRATION (FDA). Monkeypox Response. FDA, 2022. Disponível em: https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/fda-monkeypox-response. Acesso em: 20 nov. 2022.
GROSENBACH, D. W. et al. Oral Tecovirimat for the Treatment of Smallpox. New England Journal of Medicine, v. 379, n. 1, p. 44–53, 5 jul. 2018.
GUARNER, J.; DEL RIO, C.; MALANI, P. N. Monkeypox in 2022—What Clinicians Need to Know. JAMA, v. 328, n. 2, p. 139–140, 12 jul. 2022.
HARRIS, E. What to Know About Monkeypox. JAMA, v. 327, n. 23, p. 2278–2279, 21 jun. 2022.
HERMONT, A. P. et al. Revisões integrativas em Odontologia : conceitos, planejamento e execução. Arquivos Em Odontologia, v. 57, p. 3–7, 2021.
HERNANDEZ, L. E.; JADOO, A.; KIRSNER, R. S. Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat. Lancet (London, England), v. 400, n. 10355, p. e8, 10 set. 2022.
HUANG, Y.; MU, L.; WANG, W. Monkeypox: epidemiology, pathogenesis, treatment and prevention. Signal Transduction and Targeted Therapy, v. 7, n. 1, p. 1–22, 2 nov. 2022.
HUANG, Y. A. et al. Monkeypox: A clinical update for paediatricians. Journal of Paediatrics and Child Health, v. 58, n. 9, p. 1532–1538, set. 2022.
HUNG, Y.-P. et al. A brief on new waves of monkeypox and vaccines and antiviral drugs for monkeypox. Journal of Microbiology, Immunology and Infection, v. 55, n. 5, p. 795–802, 1 out. 2022.
ISLAM, MD. R. et al. Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks. Health Science Reports, v. 5, n. 5, p. e798, 2022.
KALER, J. et al. Monkeypox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation. Cureus, v. 14, n. 7, p. e26531, [s.d.].
LAM, H. Y. I.; GUAN, J. S.; MU, Y. In Silico Repurposed Drugs against Monkeypox Virus. Molecules (Basel, Switzerland), v. 27, n. 16, p. 5277, 18 ago. 2022.
LI, D. et al. Targeting F13 from monkeypox virus and variola virus by tecovirimat: Molecular simulation analysis. The Journal of Infection, v. 85, n. 4, p. e99–e101, out. 2022.
LOPES, P. S.; HADDAD, G. R.; MIOT, H. A. Varíola dos macacos de transmissão sexual: relato de dois casos. Anais Brasileiros de Dermatologia (Portuguese), v. 97, n. 6, p. 783–785, 1 nov. 2022.
LUCAR, J. et al. Monkeypox Virus-Associated Severe Proctitis Treated With Oral Tecovirimat: A Report of Two Cases. Annals of Internal Medicine, v. 175, n. 11, p. 1626–1627, nov. 2022.
MATIAS, W. R. et al. Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States. Open Forum Infectious Diseases, v. 9, n. 8, p. ofac377, 27 jul. 2022.
MCCOLLUM, A. M.; DAMON, I. K. Human Monkeypox. Clinical Infectious Diseases, v. 58, n. 2, p. 260–267, 15 jan. 2014.
MCCARTHY, M. W. Therapeutic strategies to address monkeypox. Expert Review of Anti-Infective Therapy, v. 20, n. 10, p. 1249–1252, out. 2022.
MOSCHESE, D. et al. Hospitalisation for monkeypox in Milan, Italy. Travel Medicine and Infectious Disease, v. 49, p. 102417, 2022.
NATIONAL INSTITUTES OF HEALTH (NIH). U.S. clinical trial evaluating antiviral for monkeypox begins. Disponível em: https://www.nih.gov/news-events/news-releases/us-clinical-trial-evaluating-antiviral-monkeypox-begins. Acesso em: 20 nov. 2022.
O’LAUGHLIN, K. et al. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022. MMWR. Morbidity and Mortality Weekly Report, v. 71, n. 37, p. 1190–1195, 16 set. 2022.
O’SHEA, J. Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022. MMWR. Morbidity and Mortality Weekly Report, v. 71, 2022.
PRIYAMVADA, L. et al. New methylene blue derivatives suggest novel anti-orthopoxviral strategies. Antiviral Research, v. 191, p. 105086, jul. 2021.
RIZK, John G. et al. Prevention and Treatment of Monkeypox. Drugs, [S.L.], v. 82, n. 9, p. 957-963, jun. 2022. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s40265-022-01742-y.
RUSSO, A. T. et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Review of Anti-Infective Therapy, v. 19, n. 3, p. 331–344, mar. 2021.
RUSSO, A. T. et al. Co-administration of tecovirimat and ACAM2000TM in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine, v. 38, n. 3, p. 644–654, 16 jan. 2020.
RUSSO, A. T. et al. Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques. The Journal of Infectious Diseases, v. 218, n. 9, p. 1490–1499, 22 set. 2018.
SHERWAT, A. et al. Tecovirimat and the Treatment of Monkeypox - Past, Present, and Future Considerations. The New England Journal of Medicine, v. 387, n. 7, p. 579–581, 18 ago. 2022.
SIEGRIST, C. M. et al. CRISPR/Cas9 as an antiviral against Orthopoxviruses using an AAV vector. Scientific Reports, v. 10, n. 1, p. 19307, 9 nov. 2020.
SIEGRIST, E. A.; SASSINE, J. Antivirals with Activity Against Monkeypox: A Clinically Oriented Review. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, p. ciac622, 29 jul. 2022.
SILVA, I. A. et al. Monkeypox: a transmissão pode ser realmente sexual? Revista Científica Integr@ção, v. 4, n. 1, p. 49-58, 2023.
SILVA, R. F. et al. O que precisamos saber sobre Monkeypox em humanos: fatos, não fakes. Global Academic Nursing Journal, v. 3, n. 2, p. 1-6, 2022.
SINGHAL, T.; KABRA, S. K.; LODHA, R. Monkeypox: A Review. Indian Journal of Pediatrics, v. 89, n. 10, p. 955–960, out. 2022.
SOKOLOVA, A. S. et al. (+)-Camphor and (−)-borneol derivatives as potential anti-orthopoxvirus agents. Archiv der Pharmazie, v. 354, n. 6, p. 2100038, 2021.
SOUSA, Á. F. L. DE; SOUSA, A. R. DE; FRONTEIRA, I. Monkeypox: between precision public health and stigma risk. Revista Brasileira de Enfermagem, v. 75, n. 5, p. e750501, 2022.
SRIVASTAVA, G.; SRIVASTAVA, G. Human monkeypox disease. Clinics in Dermatology, p. S0738- 081X(22)00113–4, 10 ago. 2022.
THE MEDICAL LETTER INC. Prevention and Treatment of Monkeypox, 2022. Disponível em: https://secure.medicalletter.org/TML-article-1658a. Acesso em: 1 dez. 2022
WEINSTEIN, Robert A. et al. Reemergence of Monkeypox: prevalence, diagnostics, and countermeasures. Clinical Infectious Diseases, v. 41, n. 12, p. 1765-1771, dez. 2005. Oxford University Press (OUP). http://dx.doi.org/10.1086/498155.
Downloads
Publicado
Como Citar
Licença
Copyright (c) 2023 Gabriel dos Santos Medeiros, Bruna Alves Olegário, Luiz Antônio Barbosa de Figueiredo Medeiros, Lorena Maísa Araújo Rocha Arruda, Gilberto Gomes Xavier Sobrinho, Milena Nunes Alves de Sousa
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons 
.png){kind=logo}
